未来的治疗乙型肝炎病毒感染

StephenW

Clinical Review

Clinical Journal of Gastroenterology

August 2015, Volume 8, Issue 4, pp 167-171
Future therapy for hepatitis B virus infection

    Masahito Minami


Abstract

We can now control hepatitis B virus infection by continuously administering nucleoside and nucleotide analogues such as entecavir and tenofovir. These drugs are generally safe and sufficiently effective, but future drugs are needed that can show off-treatment efficacy—in other words, eradication of latent hepatitis B virus DNA (covalently closed circular DNA) in the hepatocytes. This article is an overview of new drugs under development and some novel strategies to inhibit hepatitis B virus proliferation.
Keywords
Nucleoside analogue Cyclosporine APOBEC3 RNA interference Peptide vaccine

临床回顾

消化内科临床杂志

2015年八月，第8卷，第4期，第167-171
未来的治疗乙型肝炎病毒感染

    正人南


抽象的

现在我们可以通过连续施用核苷和核苷酸类似物，例如恩替卡韦和替诺福韦控制乙型肝炎病毒感染。这些药物通常是安全的和充分有效的，但需要未来药物可以炫耀治疗功效，换句话说，消除潜乙型肝炎病毒DNA的（共价闭合环状DNA）中的肝细胞。这篇文章是新药正在开发一些新的策略，以抑制乙肝病毒增殖的概述。
关键词
核苷类似物环孢素APOBEC3 RNA干扰肽疫苗


全文:http://download.springer.com/static/pdf/302/art%253A10.1007%252Fs12328-015-0590-y.pdf?originUrl=http%3A%2F%2Flink.springer.com%2Farticle%2F10.1007%2Fs12328-015-0590-y&token2=exp=1441968744~acl=%2Fstatic%2Fpdf%2F302%2Fart%25253A10.1007%25252Fs12328-015-0590-y.pdf%3ForiginUrl%3Dhttp%253A%252F%252Flink.springer.com%252Farticle%252F10.1007%252Fs12328-015-0590-y*~hmac=0ff7d813051ffa91f8c397279108e7d8a6c793ce084a10bf4cb9875e37d25fbe